Home/Xenothera/Bernard Vanhove

BV

Bernard Vanhove

Chief Strategic Officer

Therapeutic Areas

Oncology Infectious Diseases Immunology

Xenothera Pipeline

Drug	Indication	Phase
XON7	Solid Tumors (Lung, Prostate, Ovarian, Pancreas)	Phase 1/2
LIS22	Peripheral T-Cell Lymphoma (PTCL)	Phase 1/2
LIS1	Immunosuppression	Preclinical
XAB05/XAB06	Bacterial Infections	Preclinical
XAV19	Viral Infections	Preclinical

Leadership Team at Xenothera

Chairman, Founder & Chief Executive Officer

Françoise Shneiker

Chief Medical Officer

Chief Scientific Officer

Chief Financial Officer

Chief Production Officer

View full Xenothera profile